Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtre
Ajouter des filtres








Gamme d'année
1.
Article Dans Anglais | IMSEAR | ID: sea-92331

Résumé

A soldier presented in Jan 2002 with features of proximal myopathy and diplopia. Clinically he had features of myasthenia gravis, which was confirmed by significantly positive neostigmine test, decremental response on electrophysiological study and raised acetylcholine receptor antibody titres. He also tested positive for HIV during evaluation of a cervical lymph node detected incidentally. He responded well to neostigmine and has remained asymptomatic on follow up.


Sujets)
Anticholinestérasiques/usage thérapeutique , Comorbidité , Infections à VIH/complications , Humains , Mâle , Adulte d'âge moyen , Personnel militaire , Muscles squelettiques/anatomopathologie , Myasthénie/complications , Néostigmine/usage thérapeutique
2.
Neurol India ; 2003 Mar; 51(1): 13-5
Article Dans Anglais | IMSEAR | ID: sea-121620

Résumé

Transcranial Magnetic Stimulation (TMS) was used to evaluate the cortical excitability and central motor pathways in Parkinson's disease (PD) and correlate with severity and duration of disease. 19 cases of PD and 13 controls were enrolled. The threshold intensity (TI), cortical latency (CL), central conduction time (CCT), motor evoked potential amplitude (MEP) obtained with TMS were correlated with Hoehn and Yahr and duration of disease. The threshold intensity (TI) was significantly lower in patients of PD than controls. The TI in patients with PD was 53.16-/+8.4% patients and 67.1-/+21.6% in controls (p<0.05). This strongly correlated with duration of disease, TI being lower in patients with disease duration more than 5 years. There was no difference in the other TMS parameters - CL, CCT, MEP between patients and controls. Our study revealed increased excitability in PD which was related to longer duration of disease.


Sujets)
Sujet âgé , Cortex cérébral/physiopathologie , Stimulation électrique , Humains , Adulte d'âge moyen , Maladie de Parkinson/diagnostic , Indice de gravité de la maladie , Stimulation magnétique transcrânienne
3.
Article Dans Anglais | IMSEAR | ID: sea-90517

Résumé

Eales' disease is a primary retinal perivasculitis of an undetermined etiology seen predominantly in the Indian subcontinent. However, neurological involvement is rare. We report here a patient of retinal perivasculitis with neurological dysfunction. Our patient is a 39 years male who developed acute diminished vision right eye in March 99, which progressed for four days and remained static. In April 99 he developed acute diminished vision left eye, which progressed to near total blindness in 48 hours. He was undergoing ophthalmic evaluation. Fourty five days later he developed incoordination and weakness left half of body. The examination revealed bilateral retinal perivasculitis with pyramidal signs and left sided cerebellar signs. Investigations revealed an ESR of 40 mm at the end of first hour. His CT head revealed bilateral basal ganglionic infarcts. MRI head revealed enhancing lesions both basal ganglia and right parietal region. Cerebrospinal fluid examination showed xanthochromic fluid with markedly elevated protein and lymphocytic pleocytosis. His workup for connective tissue disorders was negative. He was put on ATT with steroids. Eales' disease is presumed allergy to tuberculoprotein. A trial of ATT with steroids has been tried with varying results. Our patient had bilateral retinal perivasculitis and neurological dysfunction. He had lymphocytic pleocytosis with markedly elevated protein in the CSF.


Sujets)
Adulte , Maladies du système nerveux central/complications , Angiographie fluorescéinique , Humains , Mâle , Rétinopathies/complications , Hémorragie de la rétine/complications , Vascularite/complications
4.
Article Dans Anglais | IMSEAR | ID: sea-85163

Résumé

Newly diagnosed patients of pulmonary tuberculosis (n = 112) were put on a rifampicin-containing drug regimen. Fifty six patients were also given a placebo tablet twice daily while the other fifty-six were given ranitidine 150 mg twice daily. Gastric pH, gastric emptying time, serum rifampicin levels, urinary total and unchanged rifampicin, serum bilirubin and ALT levels were measured serially. Clinical record of adverse symptoms was maintained. Ranitidine increased the basal as well as post-drug gastric pH without altering the gastric emptying time. Concomitant administration of ranitidine and rifampicin did not alter the absorption, metabolism or excretion of the latter but reduced the frequency of gastrointestinal symptoms.


Sujets)
Adulte , Alanine transaminase/sang , Bilirubine/sang , Interactions médicamenteuses , Femelle , Mesure de l'acidité gastrique , Motilité gastrointestinale/effets des médicaments et des substances chimiques , Humains , Mâle , Adulte d'âge moyen , Ranitidine/administration et posologie , Rifampicine/pharmacocinétique , Tuberculose pulmonaire/traitement médicamenteux
5.
Article Dans Anglais | IMSEAR | ID: sea-86312

Résumé

Clinical details and present day problems encountered in 425 cases of falciparum malaria (PF) are reported. 10.11% had taken chloroquine prior to reporting to us. Parasitic count done in 23.05% cases lacked correlation with severity of disease. Pattern of fever varied markedly but 5.4% were afebrile throughout and presented only with bodyache and malaise. Apyrexial spell was noted in 5.64%. 28.70% had typical facial looks of anaemia and sallow complexion. Cerebral symptoms were noted in 3.05%. Other symptoms were severe headache 33.4%, pain abdomen 3.29%, gastroenteritis 5.64%, jaundice 2.58% and bronchitis in 7.50%. We encountered subconjunctival haemorrhages with purpura and/or urticaria in four cases, symptoms suggestive of shock lung in 3, pulmonary oedema in 2, severe anaemia (HB less than 4 g%) in seven pregnant ladies, extrapyramidal symptoms in follow up period in 5 and congenital malaria in 2 cases. 83.25% were cured with chloroquine and oxytetracycline. 8.47% (who deteriorated despite the above treatment) were treated with quinine for 6 days. 5.17% (with severe disease) were also given quinine as first line drug. 2.82% (unresponsive to chloroquine and oxytetracycline but with mild disease) were treated with pyrimethamine-sulphamezathine combination for 5 days. One case who did not respond to quinine was treated with quinidine. Recrudescence was seen in 3.67% of patients treated with chloroquine and oxytetracycline. There was no case with renal failure, haemolysis due to G6PD deficiency and black water fever. There was only one death (0.23%) in our series. Self-medication, haphazard therapy and the slogan "Fever may be malaria-take chloroquine" can lead to problems in falciparum malaria.


Sujets)
Adolescent , Adulte , Sujet âgé , Animaux , Enfant , Enfant d'âge préscolaire , Chloroquine/usage thérapeutique , Femelle , Humains , Inde , Nourrisson , Nouveau-né , Paludisme/traitement médicamenteux , Mâle , Adulte d'âge moyen , Oxytétracycline/usage thérapeutique , Plasmodium falciparum
SÉLECTION CITATIONS
Détails de la recherche